MacroGenics, Inc.
9704 Medical Center Drive
Rockville
Maryland
20850
United States
240 articles with MacroGenics, Inc.
-
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
3/22/2023
MacroGenics, Inc. (NASDAQ: MGNX) today reported that following the U.S. Food and Drug Administration’s (FDA) approval of Incyte’s Biologics License Application (BLA) for ZYNYZ™ (retifanlimab-dlwr), the Company will receive a $15 million milestone payment from Incyte.
-
MacroGenics Provides Corporate Update and 2022 Financial Results
3/15/2023
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2022.
-
MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
3/8/2023
MacroGenics, Inc. announced that it has entered into an agreement to sell its royalty interest on future global net sales of TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust for up to $200 million.
-
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
3/7/2023
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company will release its financial results for the fourth quarter of 2022 after the market closes on Wednesday, March 15, 2023.
-
MacroGenics to Participate in Upcoming March 2023 Investor Conferences
3/2/2023
MacroGenics, Inc. announced that the Company's management will participate in the following investor conferences in March 2023:
-
MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium
2/13/2023
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary safety and anti-tumor activity data from the dose expansion phase of the Company’s ongoing Phase 1 clinical trial of lorigerlimab, a bispecific, tetravalent PD-1 × CTLA-4 DART® molecule.
-
MacroGenics to Participate in Upcoming Investor Conferences - February 06, 2023
2/6/2023
MacroGenics, Inc. announced that the Company's management will participate in the following investor conferences in February 2023:
-
MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that the company will participate in the 41st Annual J.P. Morgan Healthcare Conference.
-
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
1/4/2023
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A. Liu and Meenu Chhabra Karson to its Board of Directors, effective January 3, 2023.
-
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
11/17/2022
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S. Food and Drug Administration announced the approval of the Biologics License Application (BLA) for teplizumab, an anti-CD3 monoclonal antibody that was previously developed by MacroGenics.
-
MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results
11/3/2022
MacroGenics, Inc. provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2022.
-
MacroGenics to Participate in Upcoming November 2022 Investor Conferences
11/2/2022
MacroGenics, Inc. announced that the Company's management will participate in the following investor conferences in November 2022.
-
MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call
10/26/2022
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2022 after the market closes on Thursday, November 3, 2022.
-
Gilead Sciences and MacroGenics entered into a licensing and collaboration pact worth up to $1.7 billion to develop a bispecific antibody to treat hematological cancers.
-
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
10/17/2022
Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific research programs.
-
MacroGenics to Participate in Upcoming September 2022 Investor Conferences
9/2/2022
MacroGenics, Inc. announced that the Company's management will participate in the following investor conferences in September 2022.
-
MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results
8/8/2022
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2022.
-
MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call
7/25/2022
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter of 2022 after the market closes on Monday, August 8, 2022.
-
MacroGenics' Phase II trial shuts down after a patient death believed to be related to enoblituzumab combo, while Exelixis' Cabometyx combo improves PFS in renal cell carcinoma.
-
The study was assessing the investigational drug enoblituzumab as part of a combination therapy for head and neck cancer.